Glossary · Treatments

Denosumab (Prolia)

Also called: Prolia.

Definition: Denosumab is a monoclonal antibody against RANKL that potently inhibits osteoclast formation and activity. It is given as a subcutaneous injection every 6 months for postmenopausal osteoporosis and reduces fracture risk substantially. Stopping denosumab without follow-on therapy causes rapid bone density loss and rebound vertebral fractures.

Detailed definition

Denosumab (Prolia) is a fully human monoclonal antibody targeting RANKL (receptor activator of nuclear factor κB ligand), the cytokine that drives osteoclast differentiation, activation, and survival. It is administered as 60 mg subcutaneously every 6 months for postmenopausal osteoporosis. The FREEDOM trial demonstrated significant reductions in vertebral, nonvertebral, and hip fractures over 3 years. Long-term extension showed continued BMD gains over 10 years. Crucial caveat: discontinuation of denosumab without immediate follow-on antiresorptive therapy (typically a bisphosphonate) causes rapid loss of BMD and a substantial increase in vertebral fractures within 12–18 months. This means denosumab essentially commits patients to long-term therapy or careful sequenced transition to another agent.

Why it matters in menopause

Denosumab is a strong option for women with osteoporosis who cannot tolerate or are inadequately responsive to bisphosphonates. The discontinuation rebound effect is critical: women on denosumab should never simply stop; transition planning is essential.

Sources

External references: Wikipedia.

← Back to full glossary